Biotech deal activity picks up in Q2 2026, signaling recovery after summer slump
read at Endpoints ↗DealPositive
The biotech sector experienced a sharp decline in confidence last summer, leading to a slowdown in financing and partnership activity.
New data show that in the second quarter of 2026, dealmaking has begun to accelerate, with more announcements and negotiations compared with the previous quarter.
Analysts interpret the uptick as a sign that the market is regaining stability after the earlier crisis, though they caution that the recovery remains fragile.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Biopharma dealmaking in 2026: The recovery gathers speed in Q2”
read at Endpoints ↗65 words · retrieved Jul 22
comments(0)
5-min edit window · permanent after that